Zegers, B.J., Stoop, J.W., Reerink-Brongers, E.E., Sander, P.C., Aalberse, R.C. and Ballieux, R.E. (1975) Serum Immunoglobulins in Healthy Children and Adults. Levels of the Five Classes, Expressed in International Units Per Millilitre. Clinica Chimica Acta, 65, 319-329.
https://doi.org/10.1016/0009-8981(75)90257-0

has been cited by the following article:

• TITLE: Immunoglobulin G Specific Antibody Level against Ebola Viral Glycoprotein and Nucleoprotein in Ebola Virus Disease Survivors and Their Relatives

  AUTHORS: Nadège Goumkwa Mafopa, Raoul Emeric Guetiya Wadoum, Marta Giovanetti, Antonella Minutolo, Béatrice Dambaya, Claude Kwe Yinda, Gianluca Russo, Georges Teto, Georgia Ambada, Patrick Turay, Judith Torimiro, Alexis Ndjolo, Jules Roger Kuate, Vittorio Colizzi, Carla Montesano

  KEYWORDS: Immunoglobulin IgG Level, Ebola Survivors and Relatives, Glycoprotein and Nucleoprotein

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.9 No.4, April 30, 2021

  ABSTRACT: Ebola virus disease is a complex zoonosis that is highly virulent in humans. Despite its sorely pathogenic and lethal nature, survivors of this infection and even asymptomatic cases are able to develop both humoral and cellular immunity against several Ebola virus (EBOV) proteins. We aimed at determining immunoglobulin G (IgG) antibodies level against two Ebola viral antigens, the glycoprotein and the nucleoprotein in Ebola survivors and their relatives. Anti-EBOV glycoprotein (GP) and nucleoprotein (NP) IgG antibodies were quantified using ELISA. We enrolled 199 participants in two different sites as follow: 91 survivors at the Loreto clinic and 70 survivors with 38 relatives of Sierra Leone Association of Ebola Survivors Bombali Branch (SLAESB) tested for anti-EBOV NP and anti-EBOV GP IgG antibodies. Our findings revealed that the median anti-EBOV IgG level among survivors was 5.7128 U/ml [IQR: 2.793 - 7.783] for anti-EBOV GP IgG and 4.431 U/ml [IQR: 2.083 - 7.696] for anti-EBOV NP IgG. Survivors relatives had a median anti-EBOV GP IgG level of ?0.7128 U/ml [IQR: -0.903 to -0.04327] and -2.711 U/ml [IQR: -4.01 to -1.918] for anti-EBOV NP IgG. We observed that IgG levels in survivors were higher than in relatives with a significant difference of about 0.0001. The median value of anti-EBOV IgG level among seropositive relatives was 0.7043 U/ml [IQR: 0.5686 to 3.716] for anti-EBOV GP IgG and 4.05 U/ml [IQR: 0.2765 to 7.759] for anti-EBOV NP IgG respectively. Interestingly, we observed that 3.30% of Loreto clinic survivors did not developed anti-EBOV NP IgG antibodies; also about 10% survivors of the SLAESB were not reactive to anti-EBOV NP IgG and 1.43% of these survivors did not express antibodies against the Ebola viral glycoprotein. Our work is consistent with previous published studies showing heterogeneity in both survivors and asymptomatic cases of Ebola infection developing adaptive immunity against EBOV proteins.